UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

Antiviral research, 2015-09, Vol.121, p.47-58

2015

Volltextzugriff (PDF)

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (37), p.15127-15132

2013

Volltextzugriff (PDF)

Pharmacokinetics and Tumor Dynamics of the Nanoparticle IT-101 from Pet Imaging and Tumor Histological Measurements

Proceedings of the National Academy of Sciences - PNAS, 2009-07, Vol.106 (27), p.11394-11399

2009

Volltextzugriff (PDF)

Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models

Clinical cancer research, 2006-03, Vol.12 (5), p.1606-1614

2006

Volltextzugriff (PDF)

Cyclodextrin-Containing Polymers: Versatile Platforms of Drug Delivery Materials

Journal of Drug Delivery, 2012-01, Vol.2012 (2012), p.104-120

2012

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

Clinical pharmacology in drug development, 2017-07, Vol.6 (4), p.350-362

2017

Volltextzugriff (PDF)

CRLX101 (formerly IT-101) – A Novel Nanopharmaceutical of Camptothecin in Clinical Development

Current bioactive compounds, 2011-03, Vol.7 (1), p.8-14

2011

Volltextzugriff (PDF)

Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas

Nanomedicine, 2010-04, Vol.6 (2), p.382-390

2010

Volltextzugriff (PDF)

Cyclodextrin-Modified Polyethylenimine Polymers for Gene Delivery

Bioconjugate chemistry, 2004-07, Vol.15 (4), p.831-840

2004

Volltextzugriff (PDF)

Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy

International journal of nanomedicine, 2008-01, Vol.3 (3), p.359-371

2008

Volltextzugriff (PDF)

Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity

Clinical cancer research, 2009-01, Vol.15 (1), p.181-189

2009

Volltextzugriff (PDF)

Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models

Clinical cancer research, 2009-07, Vol.15 (13), p.4365-4373

2009

Volltextzugriff (PDF)

Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography

Journal of Chromatography A, 1998-05, Vol.806 (1), p.31-45

1998

Volltextzugriff (PDF)

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

Science translational medicine, 2017-09, Vol.9 (409)

2017

Volltextzugriff (PDF)

Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency

The New England journal of medicine, 2022-08, Vol.387 (6), p.514-524

2022

Volltextzugriff (PDF)

FRI-164 Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease

Journal of hepatology, 2024-06, Vol.80, p.S698-S698

2024

Volltextzugriff (PDF)

OS-032 Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989

Journal of hepatology, 2024-06, Vol.80, p.S27-S27

2024

Volltextzugriff (PDF)

FRI-161 Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease

Journal of hepatology, 2024-06, Vol.80, p.S696-S697

2024

Volltextzugriff (PDF)

Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB

Journal of hepatology, 2022-11, Vol.77 (5), p.1287-1298

2022

Volltextzugriff (PDF)

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

Hepatology (Baltimore, Md.), 2020-07, Vol.72 (1), p.19-31

2020

Volltextzugriff (PDF)

Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989

Gut, 2024-09, p.gutjnl-2024-333026

2024

Volltextzugriff (PDF)

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

Clinical cancer research, 2024-04, p.OF1-OF10

2024

Volltextzugriff (PDF)

Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment

Gut, 2022-04, Vol.71 (4), p.789-797

2022

Volltextzugriff (PDF)

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.339-339

2022

Volltextzugriff (PDF)

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent

Antiviral research, 2015-09, Vol.121, p.97-108

2015

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(56)
Deutsch
(45)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Pharmacokinetics and Tumor Dynamics of the Nanoparticle IT-101 from Pet Imaging and Tumor Histological Measurements

Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models

Cyclodextrin-Containing Polymers: Versatile Platforms of Drug Delivery Materials

Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

CRLX101 (formerly IT-101) – A Novel Nanopharmaceutical of Camptothecin in Clinical Development

Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas

Cyclodextrin-Modified Polyethylenimine Polymers for Gene Delivery

Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy

Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity

Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models

Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency

FRI-164 Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease

OS-032 Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989

FRI-161 Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease

Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001)

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent

Suchergebnisse filtern